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Summary Pyomyositis is an infection of skeletal muscle that involves the formation of
intramuscular abscesses. It occurs most commonly in immunocompromised patients. Pyomyositis
caused by extended-spectrum b-lactamase (ESBL)-producing Escherichia coli has never been
reported in the literature. A 48-year-old female patient developed ESBL-producing E. coli
bacteremia and pyomyositis on the twelfth day of cefpirome therapy for neutropenic fever
after chemotherapy due to acute myeloid leukemia. She recovered completely after a three-
week course of meropenem and surgical excision. Pyomyositis should be included in the
differential diagnosis when fever and muscular swelling develop in a patient with neutropenic
status after chemotherapy. Early recognition of symptoms and proper diagnostic procedures are
key to diagnosing pyomyositis. Both adequate antibiotics and surgical intervention are important
for the successful treatment of pyomyositis caused by ESBL-producing E. coli.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Pyomyositis is a purulent inflammation of skeletal muscle
that occurs in the absence of penetrating trauma or spread
from a contiguous septic focus. The pathogenesis of pyomyo-
sitis is believed to be caused by transient bacteremia in
the setting of pre-existing or concurrent muscular injury.1* Corresponding author. Department of Internal Medicine, Tri-Ser-
vice General Hospital, No. 325, Section 2, Cheng-Kung Road, Neihu
114, Taipei, Taiwan, R.O.C. Tel.: +886 2 87927257;
fax: +886 2 87927258.
E-mail address: fychang@ndmctsgh.edu.tw (F.-Y. Chang).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.06.032Pyomyositis caused by Gram-negative bacteria is a rare
complication of chemotherapy.2 We present the first case,
to our knowledge, of bacteremic pyomyositis caused by
extended-spectrum b-lactamase (ESBL)-producing Escheri-
chia coli. The 48-year-old female patient, with acutemyeloid
leukemia, was successfully treated with meropenem and
surgical excision.
Case report
A 48-year-old female, with newly diagnosed acute myeloid
leukemia, developed neutropenic fever on the 5th hospital
day. The white cell count was 20.750  109/l, the absolutePublished by Elsevier Ltd. All rights reserved.
Figure 1 Clinical course and development of pyomyositis.
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was 6.7 g/dl and the platelet count was 21.00  109/l.
Cefpirome 2 g every 12 hours was administered intrave-
nously. During the 8th to 15th days, the patient underwent
chemotherapy with daunorubicin and cytosine arabinosine
(7 and 3 regimen). On the 16th day, oral mucositis and fever
developed. Two sets of blood cultures were obtained. A
tender, swollenmass (3 cm in diameter) on her right posterior
calf, without overlying redness or warmness, was found on
the 19th day. Levels of aspartate aminotransferase, alanine
aminotransferase and creatine phosphokinase were all within
normal limits. Blood cultures revealed ESBL-producing E. coli
(resistant to all of the cephalosporins; susceptible to amiki-
cacin and imipenem) and meropenem 1 g every 8 hours was
administered from the 19th day. The clinical course and
treatment are shown in Figure 1. The mass on the right lower
leg became progressively more painful and indurate. Com-
puted tomography (CT) scans of the right lower leg revealed a
hypodense lesion, 2.8  2.6  3.5 cm in size, with peripheral
enhancement in the lateral head of the gastrocnemius mus-
cle (Figure 2A). Surgical excision of the abscess was done
(Figure 2B); bacterial culture of pus also yielded ESBL-produ-
cing E. coli. The patient recovered andwas discharged after a
three-week course of meropenem treatment.Figure 2 (A) Contrast CT scans of the lower leg, showing a 3
gastrocnemius muscle. (B) Gross view of the excisional mass.Discussion
The usual microbial cause of pyomyositis is Staphylococcus
aureus; it is seen in up to 90% of cases in tropical areas and
75% of cases in temperate countries.3 Pyomyositis caused by
Gram-negative bacteria is uncommon.1 Only six species of
Gram-negative organisms have been reported to be involved
in pyomyositis associated with hematological malignancies.
These are Aeromonas hydrophila, Serratia marcescens, Sal-
monella sp., Klebsiella pneumoniae, Pseudomonas aerugi-
nosa and Stenotrophomonas maltophilia.2 Here, we add a
unique case of pyomyositis caused by ESBL-producing E. coli
that occurred in a patient with acute myeloid leukemia.
Subclinical myopathies secondary to malignancy and che-
motherapeutic agents, and an immunocompromised status
after cancer treatment have been considered possible causes
of the development of pyomyositis in patients with hemato-
logical malignancies after chemotherapy. Experimental
skeletal muscle toxicity secondary to doxorubicin4 and vin-
cristine5 has been observed. The following classes of drugs —
anthracyclines, vinca alkaloids and corticosteroids — have
been associated with chemotherapy-related pyomyositis.6 In
this case, the scenario for pyomyositis caused by ESBL-pro-
ducing E. coli is summarized as follows. Cefpirome usedcm rim-enhanced abscess (arrow) in the lateral head of the
Pyomyositis caused by ESBL-producing E. coli e87during the period of neutropenic fever might exert a selec-
tive pressure on the ecology of normal flora and select this
ESBL-producing organism. Furthermore, chemotherapy-
induced injury to the mucosa might provide a port of entry
for bacteremia, and skeletal muscle toxicity secondary to
daunorubicin per se rendered it susceptible to infection.4
Because of the subtle clinical presentation, pyomyositis is
difficult to diagnose at an early stage. The initial symptoms of
pyomyositis include diffuse crampy pain and tenderness of
the involved area, followed by edema, low-grade fever and
leukocytosis. In later stages, the involved area becomes
indurate and might be replaced completely with pus. Pus
formation occurs 10—21 days after the initial invasive seeding
of bacteria on the muscle. Without adequate treatment, the
disease might develop to the final stage, which is character-
ized by septicemia, metastatic abscesses and multiorgan
dysfunction. Characteristically, serum levels of muscle
enzymes are normal in most patients.7 Pyomyositis should
be differentiated from hematoma, thrombosis, thromboph-
lebitis, osteomyelitis, septic arthritis and malignant tumor.
Ultrasound, CTand magnetic resonance imaging might reveal
a small focal area of fluid collection, representing pus and
fluid within the fascial planes. Definite diagnosis is made by
demonstration of the causative organism in a muscle speci-
men obtained through either biopsy or open surgery.
The mortality rate among patients infected with ESBL-
producing E. coli is threefold greater than that of patients
infectedwithnon-ESBL strains.Melzer et al8 conducteda study
of 354 patient episodes of E. coli bacteremia to investigate the
difference in clinical outcome between ESBL-producing and
non-ESBL-producing E. coli. The results found that a higher
proportion of patients died following bacteremia caused by
ESBL-producing E. coli, 28/46 (60.8%), compared to non-ESBL-
producing E. coli, 73/308 (23.7%). When facing ESBL produ-
cers, appropriate use of antibiotics is important to prevent
treatment failure. Delay in initiating an appropriate antibiotic
is significantly associated with death. Carbapenems have
demonstrated a relatively high rate of clinical success among
patients infected with ESBL producers.9
Early diagnosis, complete drainage of the purulent mate-
rial and the use of appropriate antibiotic therapy are the key
determinants of successful treatment.10 Initial antibiotic
therapy for pyomyositis should include a broad-spectrum
agent with good S. aureus coverage and subsequently can
be modified based on the culture and sensitivity results.
Coverage of Gram-negative organisms is advised to be
empirically included in the treatment of immunocompro-
mised patients. In the case of pyomyositis, treatment withan intravenous agent followed by an oral agent (when clinical
improvement has occurred) for a total of 21—28 days seems
to be appropriate. The immune status of the host, clinical
response to therapy and number of abscesses should be
considered when determining the length of therapy.1
Pyomyositis caused by ESBL-producing E. coli is a rare
complication of chemotherapy. This case reminds us that
pyomyositis should be included in the differential diagnosis
when a patient has bacteremia and a swollen and tender
muscular lesion after chemotherapy. The use of fourth-gen-
eration cephalosporins (cefpirome) for neutropenic fever
might select the ESBL-producing bacterial strain in a patient
undergoing chemotherapy for hematological malignancy.
Obtaining a microbiological culture via blood or surgical
specimen is important in order to verify the pathogen. Both
adequate antibiotics and surgical intervention are important
for the successful treatment of ESBL-producing E. coli pyo-
myositis.
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